Sandoz launches ustekinumab biosimilar in Europe
Sandoz has announced the European launch of Pyzchiva, a ustekinumab biosimilar approved for the treatment of several autoimmune conditions including…
Sandoz has announced the European launch of Pyzchiva, a ustekinumab biosimilar approved for the treatment of several autoimmune conditions including…
Sionna Therapeutics, a biopharmaceutical company dedicated to advancing treatments for cystic fibrosis (CF), has significantly strengthened its position in the…
Boehringer Ingelheim will sell an unbranded version AbbVie’s reference drug at a 92% discount to gain traction in the Humira…
AbbVie is set to expand the indication list for its immunology blockbuster, Rinvoq (upadacitinib). The company has submitted applications to…
A joint report by United Nations (UN) agencies has revealed that global immunisation coverage has stalled, remaining largely unchanged from…
German biopharmaceutical company SciRhom has secured €63m ($70m) in a Series A funding round to expedite the development of iRhom2-targeting…
Johnson & Johnson (J&J) has released positive results from the Phase III trial of nipocalimab in patients with generalised myasthenia…
Hot on the heels of securing $259m in Series C financing three months ago, Alumis has raised a further $250m…
Much like the mythological navigator from which it takes its name, Barinthus Biotherapeutics is steering a new course of pipeline…
Biogen has signed a definitive agreement to acquire clinical-stage biotechnology company Human Immunology Biosciences (HI-Bio) in a $1.8bn deal. The…